1-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-(trifluoromethyl)pyrimidine-2,4-dione is a complex chemical compound with a rather long and unwieldy name. It's more commonly known as **Leflunomide**.
**Leflunomide is a significant drug used in the treatment of rheumatoid arthritis (RA).**
Here's a breakdown of its importance in research and medicine:
* **Mechanism of Action:** Leflunomide inhibits the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme is essential for the production of pyrimidines, which are building blocks for DNA and RNA. By inhibiting DHODH, Leflunomide slows down the proliferation of immune cells, particularly T cells, which are responsible for the inflammation and tissue damage in RA.
* **Therapeutic Benefits:** Leflunomide has been proven to effectively reduce inflammation, pain, and joint damage in patients with RA. It can also slow down the progression of the disease and improve physical function.
* **Research Importance:** Leflunomide's unique mechanism of action has made it a valuable tool in research:
* **Understanding Rheumatoid Arthritis:** Leflunomide's effectiveness in treating RA highlights the importance of the immune system in the disease's pathogenesis. Further research with this drug can help unravel the intricate cellular and molecular mechanisms involved in RA.
* **Developing New Therapies:** Leflunomide's success has inspired the development of other DHODH inhibitors, some of which are being investigated for their potential in treating other autoimmune diseases like lupus and inflammatory bowel disease.
* **Cancer Research:** DHODH inhibition is also being explored as a potential therapeutic strategy in certain types of cancer, especially those with high rates of cell proliferation.
* **Clinical Significance:** Leflunomide is widely used to treat RA, and its safety and efficacy have been established through extensive clinical trials. However, like all medications, it can have side effects, and it's crucial to use it under the supervision of a physician.
In summary, Leflunomide (1-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-(trifluoromethyl)pyrimidine-2,4-dione) is a significant drug in the treatment of rheumatoid arthritis. Its unique mechanism of action makes it an important tool in research, contributing to a better understanding of RA and the development of new therapies for various diseases.
ID Source | ID |
---|---|
PubMed CID | 6708818 |
CHEBI ID | 95193 |
Synonym |
---|
MLS002154131 |
smr001233438 |
brd5570 |
brd-5570 |
BRD-A64485570-001-03-7 |
DIVK1C_007056 |
SPECTRUM_001560 |
BSPBIO_003405 |
PRESTWICK3_001056 |
SPECTRUM5_001542 |
BSPBIO_001012 |
AB00514023 |
NCGC00166323-01 |
KBIOGR_001174 |
KBIO2_004608 |
KBIO2_007176 |
KBIO1_002000 |
KBIO2_002040 |
KBIO3_002625 |
KBIOSS_002040 |
SPECPLUS_000960 |
SPECTRUM4_000617 |
SPECTRUM3_001653 |
SPECTRUM1504183 |
BPBIO1_001114 |
NCGC00178087-01 |
NCGC00178087-02 |
HMS2094O07 |
HMS1922F11 |
HMS2098C14 |
nsc759595 |
nsc-759595 |
pharmakon1600-01504183 |
HMS2234P22 |
CCG-213276 |
?,?,?-trifluorothymidine |
AKOS024458169 |
AB00053164_06 |
CHEBI:95193 |
SR-05000001890-1 |
sr-05000001890 |
SBI-0052661.P002 |
Q27167003 |
Class | Description |
---|---|
pyrimidine 2'-deoxyribonucleoside | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 5.6234 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.5481 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 1.2885 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
67.9K protein | Vaccinia virus | Potency | 0.4740 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
IDH1 | Homo sapiens (human) | Potency | 2.5929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 12.9953 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
geminin | Homo sapiens (human) | Potency | 6.5131 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 0.4324 | 0.0056 | 12.3677 | 36.1254 | AID624032; AID624044 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
exodeoxyribonuclease V subunit RecB | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 118.6480 | 0.1000 | 0.1000 | 0.1000 | AID492957 |
exodeoxyribonuclease V subunit RecC | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 118.6480 | 0.1000 | 0.1000 | 0.1000 | AID492957 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745850 | Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression | |||
AID1745846 | Firefly Luciferase Counterscreen for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745847 | CMV-Luciferase Counterscreen for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1745848 | Confirmatory qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745849 | Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression | |||
AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 8 (80.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (10.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |